MX2010004332A - Esteres de camptotecina cristalinos hidratados para el tratamiento de cancer. - Google Patents

Esteres de camptotecina cristalinos hidratados para el tratamiento de cancer.

Info

Publication number
MX2010004332A
MX2010004332A MX2010004332A MX2010004332A MX2010004332A MX 2010004332 A MX2010004332 A MX 2010004332A MX 2010004332 A MX2010004332 A MX 2010004332A MX 2010004332 A MX2010004332 A MX 2010004332A MX 2010004332 A MX2010004332 A MX 2010004332A
Authority
MX
Mexico
Prior art keywords
camptothecin
cancer
treatment
hydrated crystalline
crystalline
Prior art date
Application number
MX2010004332A
Other languages
English (en)
Spanish (es)
Inventor
Zhisong Cao
Original Assignee
Christus Stehlin Foundation Fo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Christus Stehlin Foundation Fo filed Critical Christus Stehlin Foundation Fo
Publication of MX2010004332A publication Critical patent/MX2010004332A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2010004332A 2007-10-25 2008-10-24 Esteres de camptotecina cristalinos hidratados para el tratamiento de cancer. MX2010004332A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/923,727 US7572803B2 (en) 2007-10-25 2007-10-25 Hydrated crystalline esters of camptothecin
PCT/US2008/081047 WO2009055633A1 (en) 2007-10-25 2008-10-24 Hydrated crystalline esters of camptothecin for the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2010004332A true MX2010004332A (es) 2010-05-20

Family

ID=40229972

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010004332A MX2010004332A (es) 2007-10-25 2008-10-24 Esteres de camptotecina cristalinos hidratados para el tratamiento de cancer.

Country Status (11)

Country Link
US (1) US7572803B2 (enExample)
EP (1) EP2205605B1 (enExample)
JP (1) JP5487111B2 (enExample)
KR (1) KR20100082358A (enExample)
CN (1) CN101730701B (enExample)
BR (1) BRPI0816584A2 (enExample)
CA (1) CA2703054C (enExample)
ES (1) ES2396222T3 (enExample)
MX (1) MX2010004332A (enExample)
RU (1) RU2483071C2 (enExample)
WO (1) WO2009055633A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130121921A1 (en) 2011-11-11 2013-05-16 The Christus Stehlin Foundation For Cancer Research Rodent Therapeutic Model And Methods
US9387257B2 (en) * 2014-01-17 2016-07-12 Academia Sinica Lung cancer specific peptides for targeted drug delivery and molecular imaging
US9675609B2 (en) 2015-11-11 2017-06-13 Cao Pharmaceuticals Inc. Nano- and micro-sized particles of 20-camptothecin or derivative thereof and pharmaceutical compositions containing same, and treatment of cancers therewith
US20220395497A1 (en) * 2019-11-20 2022-12-15 Vivacitas Oncology, Inc. Cancer Treatment Using Camptothecin Derivatives

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552154A (en) * 1989-11-06 1996-09-03 The Stehlin Foundation For Cancer Research Method for treating cancer with water-insoluble s-camptothecin of the closed lactone ring form and derivatives thereof
US6080751A (en) * 1992-01-14 2000-06-27 The Stehlin Foundation For Cancer Research Method for treating pancreatic cancer in humans with water-insoluble S-camptothecin of the closed lactone ring form and derivatives thereof
US5527913A (en) * 1993-02-25 1996-06-18 The Stehlin Foundation For Cancer Research Methods for purifying camptothecin compounds
US5352789A (en) * 1993-02-25 1994-10-04 The Stehlin Foundation For Cancer Research Methods for purifying camptothecin compounds
US5731316A (en) 1996-01-30 1998-03-24 The Stehlin Foundation For Cancer Research Derivatives of camptothecin and methods of treating cancer using these derivatives
US6407118B1 (en) * 1996-01-30 2002-06-18 The Stehlin Foundation For Cancer Research Derivatives of camptothecin and methods of treating cancer using these derivatives
US6096336A (en) * 1996-01-30 2000-08-01 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US5922877A (en) * 1997-08-05 1999-07-13 The Stehlin Foundation For Cancer Research Methods of preparing and purifying 9-nitro-20-camptothecin
USRE38408E1 (en) * 1997-08-05 2004-01-27 The Stehlin Foundation For Cancer Research Methods of preparing and purifying 9-nitro-20-camptothecin
US6228855B1 (en) * 1999-08-03 2001-05-08 The Stehlin Foundation For Cancer Research Aromatic esters of camptothecins and methods to treat cancers
US6352996B1 (en) * 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US6699875B2 (en) * 2002-05-06 2004-03-02 The Stehlin Foundation For Cancer Research Cascade esters of camptothecins and methods of treating cancer using these compounds
US6703399B2 (en) * 2002-05-06 2004-03-09 The Stehlin Foundation For Cancer Research Halo-alkyl esters of camptothecins and methods of treating cancer using these compounds
KR101095382B1 (ko) * 2003-02-25 2011-12-16 가부시키가이샤 야쿠르트 혼샤 이리노테칸 염산염의 결정다형의 제조방법
TWI333492B (en) * 2003-11-12 2010-11-21 Smithkline Beecham Cork Ltd Crystalline topotecan hydrochloride product and preparation thereof
WO2007035709A2 (en) * 2005-09-20 2007-03-29 Scinopharm Singapore Pte, Ltd. Novel crystal forms of irinotecan hydrochloride

Also Published As

Publication number Publication date
CN101730701B (zh) 2013-05-29
ES2396222T3 (es) 2013-02-20
US20090111845A1 (en) 2009-04-30
CA2703054C (en) 2017-08-22
RU2483071C2 (ru) 2013-05-27
RU2010120810A (ru) 2011-11-27
BRPI0816584A2 (pt) 2015-03-03
CN101730701A (zh) 2010-06-09
KR20100082358A (ko) 2010-07-16
EP2205605A1 (en) 2010-07-14
CA2703054A1 (en) 2009-04-30
JP5487111B2 (ja) 2014-05-07
JP2011500841A (ja) 2011-01-06
WO2009055633A1 (en) 2009-04-30
EP2205605B1 (en) 2012-11-21
US7572803B2 (en) 2009-08-11

Similar Documents

Publication Publication Date Title
SG10201811480WA (en) Therapeutic compounds and compositions
MX361467B (es) Compuestos de isoindolina para uso en el tratamiento de cancer.
SG170809A1 (en) Diarylthiohydantoin compounds
MX360404B (es) Compuestos para inhibir la proliferacion celular en canceres transmitidos por egfr.
MX2009006627A (es) Quinazolinas para la inhibicion de pdk1.
NZ620000A (en) Prodrug forms of kinase inhibitors and their use in cancer therapy
IN2012DN03085A (enExample)
GB2430935A (en) Tetrapeptide analogs
NZ597051A (en) Smac mimetic
MX2011009796A (es) Inhibidores de la cinasa pi3.
MX2012000709A (es) Inhibidores de pirrolopiridina de cinasas.
NZ599507A (en) Pyrazole derivatives as modulators of calcium release -activated calcium channel
EP4257591A3 (en) Inhibitors of lysine specific demethylase-1
MX2009006706A (es) Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos.
UA95310C2 (ru) Композиция, содержащая ингибитор chk1 и циклодекстрин, для лечения рака
MX2012000711A (es) Inhibidores de pirrolopirazina de cinasas.
MX342274B (es) Actividades de la piruvato quinasa m2 (pkm2).
SI1893196T2 (sl) Diarilhidantoinska spojina
MX2009013625A (es) Compuestos de di (arilamino) arilo.
GEP20115304B (en) PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
MX2010009670A (es) Conjugados de paclitaxel polimericos y metodos para tratamiento de cancer.
WO2010000364A8 (de) Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
MX2012013274A (es) Novedosos derivados de la pirimidina.
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors

Legal Events

Date Code Title Description
FG Grant or registration